摘要
目的:探讨生长抑素对肝肾综合征的治疗作用。方法:将24例Ⅰ型肝肾综合征分为两组,治疗组给予持续静滴生长抑素250μg.h-1直至肝肾综合征逆转(SCr<132.5μmol.L-1)或最长疗程7天。治疗期间治疗组和对照组均同时给予白蛋白和速尿等对症支持治疗。结果:治疗后SCr、BUN、尿量两组比较差异有统计学意义(P<0.01)。生长抑素治疗组治疗有效率为64.29%(9/14),对照组治疗有效率为20%(2/10),两组治疗有效率比较差异有统计学意义(P<0.05)。结论:使用生长抑素的综合治疗可提高肝肾综合征的治疗有效率。
Objective ：To study the therapeutic effect of somatostatin on hepatorenal syndrome. Methods： 24 patients with Ⅰ -type hepatorenal syndrome were devided into two groups. The treatment group was intravenously treated with somatostatin 250 μg·h^-1 , until SCr decreased below 132.5 μmol·L^-1 , or a maximum of 15 days. Both treatment group and control group received supportive treatment such as serum albumin and fursemide. Resuit： There was significant improvement for both groups in SCr, BUN and urine volume after treatment （P 〈 0. 01 ）. In the group of somatostatin, the efficacy rate was 64.29% （9/14）, compared with that of control group 20% （2/10）. （P 〈0. 05 ）. Conclusions： The combined somatostatin therapy can improve the efficacy rate of hepatorenal syndrome.
出处
《药学与临床研究》
2007年第6期470-472,共3页
Pharmaceutical and Clinical Research
关键词
肝硬化
肝肾综合征
生长抑素
Live cirrhosis
Hepatorenal syndrome
Somatostatin
